Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Escient Pharmaceuticals, Inc
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of CIndU (symptomatic dermographism or cold urticaria) for greater than 3 months and positive response to applicable skin provocation testing
Willing to discontinue chronic treatment with antihistamines during the study
You may not be if
Urticaria with a clear underlying etiology other than symptomatic dermographism or cold urticaria
Other active skin diseases that might confound the study evaluations (eg, atopic dermatitis, bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)
Regularly experience wheals covering the area of the body where skin testing will be conducted (eg, more than one third of the volar surface of the forearms)
Clareo Health | Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
